Reprinted in part from Future of BioPharma blog post 10/20/2015
On November 2, Michel Detheux, CEO of iTeos Therapeutics, returns as a panelist for BIO-Europe® 2015 in Munich. On that day, BIO-Europe will partner with the Alliance for Regenerative Medicine (ARM) to showcase some of the biggest movers and shakers in the cell therapy and regenerative medicine space. For a preview, you can watch Detheux at BIO-Europe 2014 on a panel with others from Novartis, Innovio and Bristol-Myers Squibb here. Their discussion focused on answering questions such as: “Are there opportunities to remain a company without having to exit?” and “Is it the endgame to get acquired?”
Is it the endgame to get acquired? – At the event last year, Detheux answered this question by commenting that his company would be running out of funds the following year and that: “If a company like iTeos wants to get access to a large portfolio of different immunotherapies we need to partner quite early stage.”
Partnership with Pfizer – In December 2014, iTeos partnered with Pfizer. iTeos gave Pfizer rights to their pre-clinical compounds targeting ID01 and TD02 while Pfizer was to be responsible for the development and commercialization of ID01 and TD02 drug candidates.